Salicylate anti-inflammatory composition Patent #: 4275059
ApplicationNo. 06/258308 filed on 04/28/1981
US Classes:514/282, One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)514/284, Tetracyclo ring system having the six-membered hetero ring as one of the cyclos514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/429, Carbocyclic ring bonded directly to the five-membered hetero ring546/44, One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)546/45, Nitrogen or divalent chalcogen double bonded directly to carbocyclic ring of the pentacyclo ring system (e.g., morphinones, etc.)546/46, A single chalcogen is bonded directly to ring carbon of the pentacyclo ring system (e.g., desoxy morphine, etc.)546/61Tetracyclo ring system having the six-membered hetero ring as one of the cyclos
ExaminersPrimary: Friedman, Stanley J.
Attorney, Agent or Firm
International ClassesA61K 9/00 (20060101)
A61K 31/35 (20060101)
A61K 31/485 (20060101)
AbstractThe invention provides a novel method of administering narcotic antagonists, narcotic analgesics and related compounds, and novel dosage forms containing those compounds which are adapted for nasal administration. The nasal dosage forms disclosed include solutions, suspensions, gels and ointments. Especially preferred compounds which can be advantageously administered in accordance with the invention include naloxone, naltrexone, nalbuphine, levorphanol, buprenorphine, butorphanol, Ɗ9 -tetrahydrocannabinol (THC), cannabidiol (CBD) and levonantradol.